



ENDING PAEDIATRIC HIV

PAEDIATRIC HIV REMAINS A GLOBAL ISSUE:

1.7 MILLION

children (0-14 years old) are living with HIV around the world¹

160,000

of new HIV infections in children are in sub-Saharan Africa²



The majority of AIDS-related deaths still occur during the first five years of life³

IN THE PAST DECADE,

there have been significant advancements made towards the UN goal of ending paediatric AIDS by 2030:⁴



- The rate of new HIV diagnoses in children has declined by 52% since 2010¹
- 52% of children with HIV have access to treatment¹
- 81% of pregnant women living with HIV had access to antiretroviral therapy (ART) to prevent transmission of HIV to their child in 2021¹

HOWEVER, THERE IS STILL PROGRESS TO BE MADE:

Paediatric HIV treatment - There is a limited availability of optimised paediatric formulations of antiretrovirals²

Vertical transmission of HIV - Without intervention, transmission rates range from 15% to 45%⁵

LEAVING NO CHILD LIVING WITH HIV BEHIND

As the only company 100% focused on HIV, we are committed to addressing the gaps in paediatric HIV treatment and management of care. If we are to reach the UN goal of ending paediatric AIDS by 2030 however, we recognise this needs to be a global effort.

At ViiV Healthcare we continue to:



Support community initiatives focused on ending paediatric AIDS and vertical transmission of HIV through our **Positive Action** programmes



Drive science and innovation in developing age-appropriate formulations⁶



Accelerate access to age-appropriate formulations across the globe so that children living with HIV have access to optimal treatment⁷

By collaborating with the global HIV community, we hope to maintain momentum towards our collective goal and get closer to ending paediatric AIDS.

To find out more about paediatric HIV care, please visit: <https://viihealthcare.com/ending-hiv/stories/commitment-to-global-health/paediatric-hiv-care/>

References:

¹ UNAIDS. Global HIV & AIDS Statistics – 2022 Fact Sheet. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed May 2023. ² UNAIDS. In Danger: UNAIDS Global AIDS Update. Available at: https://www.unaids.org/sites/default/files/media_asset/2022-global-aids-update_en.pdf. Accessed May 2023. ³ UNAIDS. Get on the fast-track. The life-cycle approach to HIV. Available at: https://www.unaids.org/sites/default/files/media_asset/Get-on-the-Fast-Track_en.pdf. Accessed May 2023. ⁴ UNAIDS. The Global Alliance to end AIDS in Children. Available at: https://www.unaids.org/sites/default/files/media_asset/global-alliance-end-AIDS-in-children_en.pdf. Accessed May 2023. ⁵ World Health Organization. Mother-to-child transmission of HIV. Available at: <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/mother-to-child-transmission-of-hiv#:~:text=Globally%2C%20an%20estimated%201.3%20million,from%2015%25%20to%2045%25>. Accessed May 2023. ⁶ ViiV Healthcare. US FDA approval of the first-ever dispersible tablet formulation of dolutegravir. June 2020. Available at: <https://viihealthcare.com/en-gb/media/press-releases/2020/june/vii-healthcare-announces-us-fda-approval-of-the-first-ever-disp>. Accessed May 2023. ⁷ ViiV Healthcare. Innovative Public-Private Partnership Initiative to improve the lives of CLHIV. Available at: <https://viihealthcare.com/en-gb/media/press-releases/2018/july/innovative-public-private-partnership-initiative-to-accelerate-development-of-optimal-pediatric-formulations-of-dolutegravir-to-improve-the-lives-of-clhiv/>. Accessed May 2023.

